Oppenheimer Starts Coverage of Genomic Health, Thermo Fisher Scientific, Fluidigm | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Oppenheimer has initiated coverage of Genomic Health, Thermo Fisher Scientific, and Fluidigm.

In a research note issued after the close of the market on Tuesday, analyst David Ferreiro placed a Perform rating on Genomic Health and a 12- to 18-month price target on its stock of $20. He estimated the firm's 2011 EPS at $.11 on revenues of $204.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.